Skip directly to search Skip directly to A to Z list Skip directly to navigation Skip directly to page options Skip directly to site content


Hot Topics of the Day|PHGKB
Search PHGKB:

Archive

Hot Topics of the Day are picked by experts to capture the latest information and publications on public health genomics and precision health for various diseases and health topics. Sources include published scientific literature, reviews, blogs and popular press articles.

Search Archive:
79 hot topic(s) found with the query "Cervical cancer"

A Novel HPV/Host DNA Methylation-Score and Detection of Cervical Adenocarcinoma.
Ana Gradissimo et al. J Natl Cancer Inst 2023 7 (Posted: Jul 23, 2023 9AM)

The widespread introduction of Pap testing in the 1960second was followed by significant reductions in the incidence of cervical squamous cell cancer (SCC). However, the incidence of cervical adenocarcinoma (ADC) did not decrease, likely because of low Pap test sensitivity for ADC and adenocarcinoma in situ (AIS). This study assessed a novel HPV/host DNA Methylation-Score for AIS/ADC screening.

The WID-CIN test identifies women with, and at risk of, cervical intraepithelial neoplasia grade 3 and invasive cervical cancer
JE Barrett et al, Genome Medicine, October 19, 2022 (Posted: Oct 19, 2022 7AM)

We developed the WID-CIN (Women’s cancer risk IDentification-Cervical Intraepithelial Neoplasia) test, a DNA methylation signature consisting of 5000 CpG sites. The receiver operating characteristic area under the curve (AUC) in the independent diagnostic validation set was 0.92 (95% CI 0.88–0.96). At 75% specificity (=CIN1), the overall sensitivity to detect CIN3+ is 89.7% (83.3–96.1) in all and 92.7% (85.9–99.6) and 65.6% (49.2–82.1) in women aged =30 and <30.

Extended human papillomavirus genotyping to predict progression to high-grade cervical precancer: A prospective cohort study in the southeastern United States.
Bukowski Alexandra et al. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2022 6 (Posted: Jun 05, 2022 7AM)

We assessed a US-based prospective, multiracial, clinical cohort of 343 colposcopy patients with normal histology (n=226) or CIN1 (n=117). Baseline cervical samples underwent HPV DNA genotyping, and participants were followed up to five years. Non-16/18 hrHPV types are associated with differential CIN2+ progression rates. HPV16, 33, and 58 exhibited the highest rates over five years. HPV risk groups warrant further investigation in diverse US populations

Novel artificial intelligence machine learning approaches to precisely predict survival and site-specific recurrence in cervical cancer: A multi-institutional study.
Guo Chenyan et al. Translational oncology 2021 14(5) 101032 (Posted: Feb 26, 2021 2PM)

Machine learning (ML) has been gradually integrated into oncologic research but seldom applied to predict cervical cancer (CC), and no model has been reported to predict survival and site-specific recurrence simultaneously. Thus, we aimed to develop ML models to predict survival and site-specific recurrence in CC and to guide individual surveillance.

Genetic markers and phosphoprotein forms of beta-catenin pβ-Cat552 and pβ-Cat675 are prognostic biomarkers of cervical cancer
SM Scholl et al, EBiomedicine, October 21, 2020 (Posted: Oct 22, 2020 9AM)

Survival analysis on 89 patients with all omics data available, suggested loss-of-function (LOF) or activating molecular alterations in nine genes to be candidate biomarkers for worse prognosis in patients treated by chemo-radiation while LOF of ATRX, MED13 as well as CASP8 were associated with better prognosis.

AI dual-stain approach improved accuracy, efficiency of cervical cancer screening in NCI study
NCI, June 2020 Brand (Posted: Jun 30, 2020 8AM)

In recent years, clinicians have hoped to take advantage of advances in digital imaging and machine learning to improve cervical cancer screening. The challenge is to identify which women with positive HPV test results are most likely to have precancerous changes in their cervical cells.

Validation of New High Throughput, Low Cost HPV Test for Cervical Cancer Prevention
NCI, August 6, 2019 Brand (Posted: Aug 08, 2019 8AM)

A next-generation sequencing assay for detection of 51 types of human papillomavirus (HPV)provides a high-throughput, low cost, and reliable method of detecting cervical precancer and estimating HPV vaccination efficacy.

The precision prevention and therapy of HPV-related cervical cancer: new concepts and clinical implications.
Hu Zheng et al. Cancer medicine 2018 Oct (10) 5217-5236 (Posted: Mar 04, 2019 8AM)

From HPV Infection to Lesion Progression: The Role of HLA Alleles and Host Immunity.
Paaso Anna et al. Acta cytologica 2019 Feb 1-11 (Posted: Mar 04, 2019 8AM)

Using Artificial Intelligence to Detect Cervical Cancer
NIH Director's Blog, January 17, 2019 Brand (Posted: Jan 19, 2019 7AM)

Preventing Cervical Cancer in the 21st Century
CDC Public Health Grand Rounds, January 15, 2018 Brand (Posted: Jan 15, 2019 9AM)

Final Recommendation Statement Cervical Cancer Screening,
U.S. Preventative Services Task Force, August 2018 (Posted: Aug 29, 2018 9AM)

Cervical Cancer Screening—Moving From the Value of Evidence to the Evidence of Value
GF Sawaya, JAMA Internal Medicine, AUgust 21, 2018 (Posted: Aug 21, 2018 0PM)

Screening for Cervical Cancer- New Tools and New Opportunities
LA Learman et al, JAMA, August 21, 2018 (Posted: Aug 21, 2018 0PM)

Protect Your Daughters from Cervical Cancer
Brand (Posted: Jan 22, 2018 1PM)

Genetic susceptibility in cervical cancer: From bench to bedside.
Bahrami Afsane et al. Journal of cellular physiology 2018 Mar (3) 1929-1939 (Posted: Jan 07, 2018 8AM)

Putative biomarkers for cervical cancer: SNVs, methylation and expression profiles.
Cardoso Maria de Fátima Senra et al. Mutation research 2017 Jul 161-173 (Posted: Jan 07, 2018 8AM)

Largest Genomic Study of Cervical Cancer Identifies Novel Targets for Therapy
Cervical Cancer News, January 30, 2017 (Posted: Feb 01, 2017 3PM)

TCGA study identifies genomic features of cervical cancer
National Cancer Institute, January 23, 2017 (Posted: Jan 31, 2017 7AM)

Virtues and Weaknesses of DNA Methylation as a Test for Cervical Cancer Prevention.
Lorincz Attila T et al. Acta cytologica 2016 (6) 501-512 (Posted: Jan 24, 2017 0PM)

New Genomic Study Provides In-Depth Characterization of Cervical Cancer
Clinical Omics, January 24, 2017 (Posted: Jan 24, 2017 0PM)

Cost-effective management of women with minor cervical lesions: Revisiting the application of HPV DNA testing.
Pedersen Kine et al. Gynecologic oncology 2016 Nov 143(2) 326-333 (Posted: Oct 26, 2016 10AM)

Development of a clinical decision support system using genetic algorithms and Bayesian classification for improving the personalised management of women attending a colposcopy room.
Bountris Panagiotis et al. Healthcare technology letters 2016 Jun 3(2) 143-9 (Posted: Jul 13, 2016 9AM)

EileenÂ’s Cancer Survivor Story
I had a family history of cervical and uterine cancers but I didn?t get checked until I had symptoms. Brand (Posted: Jan 13, 2016 11AM)

Deep sequencing of HPV16 genomes: A new high-throughput tool for exploring the carcinogenicity and natural history of HPV16 infection.
Cullen Michael et al. Papillomavirus research 2015 Dec 3-11 (Posted: Jan 11, 2016 1PM)

Chromosomal copy number alterations and HPV integration in cervical precancer and invasive cancer.
Bodelon Clara et al. Carcinogenesis 2015 Dec (Posted: Jan 11, 2016 1PM)

Genetic diversity of HPV16 and HPV18 in Brazilian patients with invasive cervical cancer.
Vidal Joao Paulo C B et al. Journal of medical virology 2015 Dec (Posted: Jan 11, 2016 1PM)

A Suggested Approach to Simplify and Improve Cervical Screening in the United States.
Schiffman Mark et al. Journal of lower genital tract disease 2016 Jan (1) 1-7 (Posted: Jan 11, 2016 1PM)

Comprehensive mapping of the human papillomavirus (HPV) DNA integration sites in cervical carcinomas by HPV capture technology.
Liu Ying et al. Oncotarget 2015 Dec (Posted: Jan 11, 2016 1PM)

Cervical Cancer Awareness
Brand (Posted: Jan 11, 2016 1PM)

HER2 as a novel therapeutic target for cervical cancer.
Oh Doo-Yi et al. Oncotarget 2015 Nov (34) 36219-30 (Posted: Jan 05, 2016 0PM)

Genomic profile predicts the efficacy of neoadjuvant chemotherapy for cervical cancer patients.
Horikawa Naoki et al. BMC cancer 2015 739 (Posted: Jan 05, 2016 0PM)

MicroRNAs are involved in cervical cancer development, progression, clinical outcome and improvement treatment response (Review).
González-Quintana Víctor et al. Oncology reports 2016 Jan (1) 3-12 (Posted: Jan 05, 2016 0PM)

Protect Your Daughters from Cervical Cancer
Brand (Posted: Jan 05, 2016 0PM)

From prospective biobanking to precision medicine: BIO-RAIDs - an EU study protocol in cervical cancer.
Ngo Charlotte et al. BMC cancer 2015 842 (Posted: Nov 06, 2015 9AM)

Lynch Syndrome and Cervical Cancer.
Antill Yoland C et al. Int. J. Cancer 2015 Jun 15. (Posted: Jul 09, 2015 3PM)

Estimation of Detection Rates of Aneuploidy in High-Risk Pregnancy Using an Approach Based on Nuchal Translucency and Non-Invasive Prenatal Testing: A Cohort Study.
Khalil Asma et al. Fetal. Diagn. Ther. 2015 Apr 30. (Posted: May 06, 2015 10AM)

"Suddenly Having two Positive People who are Carriers is a Whole New Thing"- Experiences of Couples Both Identified as Carriers of Cystic Fibrosis Through a Population-Based Carrier Screening Program in Australia.
Ioannou Liane et al. J Genet Couns 2015 May 1. (Posted: May 06, 2015 10AM)

Genetics and Personal Insurance: the Perspectives of Canadian Cancer Genetic Counselors.
Lane Michelle et al. J Genet Couns 2015 May 1. (Posted: May 06, 2015 10AM)

Attitudes and Knowledge of Maternal-Fetal Medicine Fellows Regarding Noninvasive Prenatal Testing.
Swaney Paul et al. J Genet Couns 2015 May 1. (Posted: May 06, 2015 10AM)

A survey on the awareness and attitude of pharmacists and doctors towards the application of pharmacogenomics and its challenges in Qatar.
Elewa Hazem et al. J Eval Clin Pract 2015 Apr 30. (Posted: May 06, 2015 10AM)

Patentability of human genes: the conceptual differences between the industrialised and Latin American countries.
Bergel Salvador Darío et al. J Community Genet 2015 May 1. (Posted: May 06, 2015 10AM)

Family history and body mass index predict perceived risks of diabetes and heart attack among community-dwelling Caucasian, Filipino, Korean, and Latino Americans-DiLH Survey.
Fukuoka Yoshimi et al. Diabetes Res. Clin. Pract. 2015 Apr 20. (Posted: May 06, 2015 10AM)

"Don't Want No Risk and Don't Want No Problems": Public Understandings of the Risks and Benefits of Non-Invasive Prenatal Testing in the United States.
Allyse Megan et al. AJOB Empir Bioeth 6(1) 5-20 (Posted: May 06, 2015 10AM)

Use of modified Magee equations and histologic criteria to predict the Oncotype DX recurrence score.
Turner Bradley M et al. Mod. Pathol. 2015 May 1. (Posted: May 06, 2015 10AM)

Adherence patterns to National Comprehensive Cancer Network (NCCN) guidelines for referral to cancer genetic professionals.
Febbraro Terri et al. Gynecol. Oncol. 2015 Apr 28. (Posted: May 06, 2015 10AM)

An update on the use of health information technology in newborn screening.
Abhyankar Swapna et al. Semin. Perinatol. 2015 Apr 29. (Posted: May 06, 2015 10AM)

Family history of premature myocardial infarction, life course socioeconomic position and coronary heart disease mortality - A Cohort of Norway (CONOR) study.
Fiskå Bendik S et al. Int. J. Cardiol. 2015 Apr 22. 190302-307 (Posted: May 06, 2015 10AM)

Newborn screening: evolving challenges in an era of rapid discovery.
Bailey Donald B et al. JAMA 2015 Apr 21. 313(15) 1511-2 (Posted: May 06, 2015 10AM)

Whole-genome sequencing in critically ill infants and emerging ethical challenges.
Char Danton S et al. Lancet Respir Med 2015 Apr 27. (Posted: May 06, 2015 10AM)

Whole-genome sequencing for identification of Mendelian disorders in critically ill infants: a retrospective analysis of diagnostic and clinical findings.
Willig Laurel K et al. Lancet Respir Med 2015 Apr 27. (Posted: May 06, 2015 10AM)

The Pediatric Imaging, Neurocognition, and Genetics (PING) Data Repository.
Jernigan Terry L et al. Neuroimage 2015 Apr 30. (Posted: May 06, 2015 10AM)

Effects of CYP2C19 and P2Y12 Gene Polymorphisms on Clinical Results of Patients Using Clopidogrel after Acute Ischemic Cerebrovascular Disease.
Sen H M et al. Balkan J. Med. Genet. 2014 Dec 17(2) 37-41 (Posted: May 06, 2015 10AM)

Ethical, legal, social, and policy issues in the use of genomic technology by the U.S. Military.
Mehlman Maxwell J et al. J Law Biosci 2014 Sep 1. 1(3) 244-280 (Posted: May 06, 2015 10AM)

The impact of smoke exposure on the clinical phenotype of alpha-1 antitrypsin deficiency in ireland: exploiting a national registry to understand a rare disease.
O'Brien M Emmet et al. COPD 2015 May 12 Suppl 12-9 (Posted: May 06, 2015 10AM)

Alpha-1 antitrypsin deficiency in Canada: regional disparities in diagnosis and management.
Bradi Ana C et al. COPD 2015 May 12 Suppl 115-21 (Posted: May 06, 2015 10AM)

The national alpha-1 antitrypsin deficiency registry in poland.
Chorostowska-Wynimko Joanna et al. COPD 2015 May 12 Suppl 122-6 (Posted: May 06, 2015 10AM)

The Clinical Profile of Subjects Included in the Swedish National Register on Individuals with Severe Alpha 1-Antitrypsin deficiency.
Piitulainen Eeva et al. COPD 2015 May 12 Suppl 136-41 (Posted: May 06, 2015 10AM)

The United States alpha-1 foundation research registry: genesis, impact and future.
Strange Charlie et al. COPD 2015 May 12 Suppl 142-5 (Posted: May 06, 2015 10AM)

Italian registry of patients with alpha-1 antitrypsin deficiency: general data and quality of life evaluation.
Luisetti Maurizio et al. COPD 2015 May 12 Suppl 152-7 (Posted: May 06, 2015 10AM)

Using community-based participatory research principles to develop more understandable recruitment and informed consent documents in genomic research.
Skinner Harlyn G et al. PLoS ONE 2015 10(5) e0125466 (Posted: May 06, 2015 10AM)

PGMD: a comprehensive manually curated pharmacogenomic database.
Kaplun A et al. Pharmacogenomics J. 2015 May 5. (Posted: May 06, 2015 10AM)

Early prediction of disease progression in small-cell lung cancer: Towards model-based personalized medicine in oncology.
Buil-Bruna Nuria et al. Cancer Res. 2015 May 4. (Posted: May 06, 2015 10AM)

Medium-Chain Acyl-CoA Dehydrogenase Deficiency: Evaluation of Genotype-Phenotype Correlation in Patients Detected by Newborn Screening.
Gramer Gwendolyn et al. JIMD Rep 2015 May 5. (Posted: May 06, 2015 10AM)

No Clinical Utility of KRAS Variant rs61764370 for Ovarian or Breast Cancer.
et al. Gynecol. Oncol. 2015 May 1. (Posted: May 06, 2015 10AM)

An Adolescent Substance Prevention Model Blocks the Effect of CHRNA5 Genotype on Smoking During High School.
Vandenbergh David J et al. Nicotine Tob. Res. 2015 May 4. (Posted: May 06, 2015 10AM)

Cervical Cancer Screening in Average-Risk Women.
Ann. Intern. Med. 2015 Apr 30. (Posted: May 06, 2015 10AM)

Global methylation silencing of clustered proto-cadherin genes in cervical cancer: serving as diagnostic markers comparable to HPV.
Wang Kai-Hung et al. Cancer Med 2015 Jan (1) 43-55 (Posted: May 06, 2015 9AM)

Progression of naive intraepithelial neoplasia genome to aggressive squamous cell carcinoma genome of uterine cervix.
Jung Seung-Hyun et al. Oncotarget 2015 Feb 28. (6) 4385-93 (Posted: May 06, 2015 9AM)

Assessment of the association between micronuclei and the degree of uterine lesions and viral load in women with human papillomavirus.
Adam Mônica Lúcia et al. Cancer Genomics Proteomics 2015 Mar-Apr (2) 67-71 (Posted: May 06, 2015 9AM)

Quantitative DNA methylation analysis of candidate genes in cervical cancer.
Siegel Erin M et al. PLoS ONE 2015 (3) e0122495 (Posted: May 06, 2015 9AM)

Can Genomic Amplification of Human Telomerase Gene and C-MYC in Liquid-Based Cytological Specimens Be Used as a Method for Opportunistic Cervical Cancer Screening?
Gao Kun et al. Gynecol. Obstet. Invest. 2015 Apr 1. (Posted: May 06, 2015 9AM)

Cervical Cancer Screening in Average-Risk Women: Best Practice Advice From the Clinical Guidelines Committee of the American College of Physicians.
Sawaya George F et al. Ann. Intern. Med. 2015 Apr 30. (Posted: May 06, 2015 9AM)

Fact Sheet on Cervical Cancer [PDF 873.72 KB]
Brand (Posted: Feb 25, 2015 0PM)

Cervical cancer is preventable
Brand (Posted: Feb 25, 2015 0PM)

What should I know about screening?
Brand (Posted: Feb 25, 2015 0PM)

The Cancer Genome Atlas
Brand (Posted: Jan 11, 2014 11AM)

The Cancer Genome Atlas (TCGA) has chosen cancers for study based on specific criteria that include: &#9726;Poor prognosis and overall public health impact &#9726;Availability of human tumor and matched-normal tissue samples that meet TCGA standards for patient consent, quality and quantity Below is a list of cancers that have been selected for study based on the criteria outlined above. The TCGA program has collected the necessary quality and quantity of samples for these cancers to move them into the TCGA project pipeline. Scheduling for sequencing and characterization for these cancers will be dependent on the capacity of the project pipeline. To view TCGA's clinical data forms, please visit the Biospecimen Core Resource's website. TCGA is no longer accepting additional samples for characterization. Analysis is underway in the following Analysis Working Groups (AWGs): &#9726;Cervical cancer &#9726;Cholangiocarcinoma &#9726;Esophageal carcinoma &#9726;Liver hepatocellular carcinoma &#9726;Mesothelioma &#9726;Pancreatic ductal adenocarcinoma &#9726;Paraganglioma & Pheochromocytoma &#9726;Sarcoma &#9726;Testicular germ cell cancer &#9726;Thymoma &#9726;Uterine carcinosarcoma &#9726;Uveal melanoma

Bringing Precision to Screening for Cancer
Brand (Posted: Jan 11, 2014 11AM)

Precision medicine is most often discussed in the context of treatment, but cancer control and prevention researchers are applying these concepts to cancer screening. Largely, that means finding ways to pinpoint who is most likely to benefit from regular screening. On September 29, NCI sponsored a conference that brought together leading screening and cancer control researchers to discuss the state of the science of precision screening for five cancers: prostate, breast, colorectal, cervical, and lung. The intent of the meeting was to allow the researchers "to brainstorm about how best to move forward" with a research agenda for better understanding and implementing precision screening, explained its chief organizer, Pam Marcus, Ph.D., of NCI?s Epidemiology and Genomics Research Program. A surprising theme that emerged from the meeting, Dr. Marcus said, was that although there are some common issues and challenges for precision screening for these five cancers, in many cases, the issues and challenges "are very organ specific." Harms and Benefits In recent years the risk of overdiagnosis and overtreatment associated with cancer screening?in particular, screening for breast and prostate cancer?has come under intense scrutiny. The need to reduce those risks was an undercurrent throughout the conference. "All screening programs can do harm, but some can do good," said Nora Pashayan, M.D., Ph.D., of the University College London, during her keynote address. ?What matters is the balance of potential benefits versus potential harms.? Michael Gould, M.D., of Kaiser Permanente Southern California, highlighted the challenges that lung cancer screening can present. Dr. Gould pointed to the changes that have come about as a result of the National Lung Screening Trial (NLST), which showed that current and former heavy smokers were 20 percent less likely to die from lung cancer if they were screened with low-dose helical CT than if they were screened with standard chest x-rays. But, he noted, the trial also had a very high percentage of false-positive results, which translated into approximately 2 percent of participants undergoing an invasive procedure?either a biopsy or surgery?for what turned out to be a benign lung nodule. Based on the NLST results, Medicare and many other insurers now cover the cost of screening with CT in current or prior heavy smokers. But that change has not come without problems, Dr. Gould noted. As was the case in NLST, he said, many current and former smokers who are now coming in for screening have false-positive results and are undergoing additional tests, including invasive procedures?which can have their own, sometimes serious, complications. Researchers are studying ways to better stratify these people by their cancer risk, and Dr. Gould described some of this work. But, in the absence of more definitive information on risk beyond smoking history, he acknowledged that, at his institution, "we?re still struggling with how to implement screening in the real world." Progress toward Risk-Tailored Screening In breast cancer, there has been considerable study of precision screening, also referred to as risk-tailored screening, explained Dr. Pashayan. But, echoing a refrain heard throughout the day, she acknowledged that in this area "there are more questions than answers." In breast and other cancers, factors such as family history, age, and clinical history are often used to predict future cancer risk, which can help guide screening decisions. Dr. Pashayan and other researchers have been studying whether additional information, such as panels of genetic alterations known as single-nucleotide polymorphisms (SNPs)?identified via genome-wide association studies?can help to improve risk stratification. She cited a recent large study that indicated that a "polygenic risk score"?based on how many risk variants associated with breast cancer a woman has?can identify women at increased breast cancer risk. In the study, women with the highest polygenic risk score, for example, had a risk of breast cancer that was three times greater than that of women who had lower scores. Although these results suggest that there is some promise to using this type of genetic information to help identify those who might benefit most from screening, many of these types of studies?in breast but also other cancers?are still preliminary and will need to be refined and validated, Dr. Pashayan noted. "We will need robust evidence to support precision medicine screening," she said. Some Movement toward More Precision Cervical cancer screening in the United States has already moved toward a risk-based approach, said Mark Schiffman, M.D., M.P.H., of NCI?s Division of Cancer Epidemiology and Genetics (DCEG). The shift, he explained, is based on studies which established that persistent infection with high-risk types of human papillomavirus (HPV) are responsible for nearly all cases of cervical cancer and that revealed the process by which precancerous lesions progress to an invasive cancer. "We know a great deal about the causal pathway in cervical cancer," Dr. Schiffman said. Although Pap testing is still being used routinely to screen women for cervical cancer, clinicians are now incorporating a patient?s HPV status into the decision-making process, Dr. Schiffman said. Under current recommendations from leading medical societies, the presence of high-risk HPV types, identified using DNA-based tests, should help to guide decisions about issues such as the most appropriate screening interval. But the current approach is not set in stone, Dr. Schiffman cautioned. As rates of vaccination against HPV increase, he explained, that will affect how cervical cancer screening is performed. Challenges Remain There was also robust discussion about what type of evidence is needed to implement changes in screening practices: primarily data from observational, population-based studies or data from randomized controlled trials. Dependent on the cancer type and the extent and strength of the available data, there is evidence to support both views, Dr. Marcus noted. Working through these sorts of questions will be a key challenge in moving toward a precision medicine-based approach to screening, she added. Although there is still a long way to go before precision screening is common for these cancers, Dr. Gould stressed that it?s important to keep moving in this direction. "When we?re screening, we?re dealing with otherwise healthy people, and we?re turning them into patients," he said. "We need to do everything we can to [screen people] safely and minimize harms." Cancer

Familial risk of Sjögren's syndrome and co-aggregation of autoimmune diseases in affected families: A nationwide population study.
Kuo Chang-Fu et al. 2015 May 4. (Posted: Jan 01, 2014 0AM)


Disclaimer: Articles listed in Hot Topics of the Day are selected by Public Health Genomics Branch to provide current awareness of the scientific literature and news. Inclusion in the update does not necessarily represent the views of the Centers for Disease Control and Prevention nor does it imply endorsement of the article's methods or findings. CDC and DHHS assume no responsibility for the factual accuracy of the items presented. The selection, omission, or content of items does not imply any endorsement or other position taken by CDC or DHHS. Opinion, findings and conclusions expressed by the original authors of items included in the Clips, or persons quoted therein, are strictly their own and are in no way meant to represent the opinion or views of CDC or DHHS. References to publications, news sources, and non-CDC Websites are provided solely for informational purposes and do not imply endorsement by CDC or DHHS.
TOP